{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:26:58Z","timestamp":1790746018354,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40271-025-00741-x","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T14:01:46Z","timestamp":1747144906000},"page":"511-521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Patients\u2019 Experiences of Atopic Dermatitis and Nemolizumab Treatment: An In-Trial Interview Study Embedded in a Phase 3 Clinical Trial (ARCADIA)"],"prefix":"10.1007","volume":"18","author":[{"given":"Jonathan I.","family":"Silverberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Filipenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Dias Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chambenoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Piketty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Puelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"issue":"12","key":"741_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra2023911","volume":"384","author":"S Stander","year":"2021","unstructured":"Stander S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136\u201343.","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"741_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13223-018-0281-6","volume":"14","author":"S Kapur","year":"2018","unstructured":"Kapur S, Watson W, Carr S. Atopic dermatitis. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):52.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"9","key":"741_CR3","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1111\/exd.14401","volume":"30","author":"G Ingrasci","year":"2021","unstructured":"Ingrasci G, et al. The pruritogenic role of the type 2 immune response in diseases associated with chronic itch. Exp Dermatol. 2021;30(9):1208\u201317.","journal-title":"Exp Dermatol"},{"issue":"2","key":"741_CR4","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jaad.2018.09.035","volume":"80","author":"YW Yew","year":"2019","unstructured":"Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J Am Acad Dermatol. 2019;80(2):390\u2013401.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"741_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/DER.0000000000000401","volume":"29","author":"JC Li","year":"2018","unstructured":"Li JC, et al. Sleep disturbance and sleep-related impairment in adults with atopic dermatitis: a cross-sectional study. Dermatitis. 2018;29(5):270\u20137.","journal-title":"Dermatitis"},{"issue":"3","key":"741_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jaad.2007.10.010","volume":"58","author":"BG Bender","year":"2008","unstructured":"Bender BG, et al. Disease severity, scratching, and sleep quality in patients with atopic dermatitis. J Am Acad Dermatol. 2008;58(3):415\u201320.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"741_CR7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s13555-017-0192-3","volume":"7","author":"C Jeon","year":"2017","unstructured":"Jeon C, et al. Frequency and management of sleep disturbance in adults with atopic dermatitis: a systematic review. Dermatol Ther (Heidelb). 2017;7(3):349\u201364.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"741_CR8","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s40257-018-0381-6","volume":"19","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, et al. A comprehensive conceptual model of the experience of chronic itch in adults. Am J Clin Dermatol. 2018;19(5):759\u201369.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"741_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/jid.2014.325","volume":"135","author":"JI Silverberg","year":"2015","unstructured":"Silverberg JI, et al. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. J Investig Dermatol. 2015;135(1):56\u201366.","journal-title":"J Investig Dermatol"},{"issue":"2","key":"741_CR10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.anai.2019.04.020","volume":"123","author":"JI Silverberg","year":"2019","unstructured":"Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123(2):144\u201351.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"741_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12787","volume":"32","author":"A Dattola","year":"2019","unstructured":"Dattola A, et al. What\u2019s new in the treatment of atopic dermatitis? Dermatol Ther. 2019;32(2): e12787.","journal-title":"Dermatol Ther"},{"issue":"5","key":"741_CR12","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s40257-022-00712-0","volume":"23","author":"E Kleinman","year":"2022","unstructured":"Kleinman E, et al. What\u2019s new in topicals for atopic dermatitis? Am J Clin Dermatol. 2022;23(5):595\u2013603.","journal-title":"Am J Clin Dermatol"},{"key":"741_CR13","doi-asserted-by":"publisher","first-page":"adv00830","DOI":"10.2340\/actadv.v102.3932","volume":"102","author":"M Augustin","year":"2022","unstructured":"Augustin M, et al. Real-world treatment patterns and treatment benefits among adult patients with atopic dermatitis: results from the Atopic Dermatitis Patient Satisfaction and Unmet Need Survey. Acta Derm Venereol. 2022;102:adv00830.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"741_CR14","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1610-0387.2007.06609.x","volume":"6","author":"J Schmitt","year":"2008","unstructured":"Schmitt J, et al. Determinants of treatment goals and satisfaction of patients with atopic eczema. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 2008;6(6):458\u201365.","journal-title":"JDDG Journal der Deutschen Dermatologischen Gesellschaft"},{"issue":"5","key":"741_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s40271-024-00698-3","volume":"17","author":"KC Heinz","year":"2024","unstructured":"Heinz KC, et al. Treatment preference research in atopic dermatitis: a systematic review of quantitative studies. Patient Patient Cent Outcomes Res. 2024;17(5):519\u201335.","journal-title":"Patient Patient Cent Outcomes Res"},{"issue":"7","key":"741_CR16","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.ad.2021.12.014","volume":"113","author":"E Serra-Baldrich","year":"2022","unstructured":"Serra-Baldrich E, Santamaria-Babi LF, Francisco Silvestre J. Nemolizumab: an innovative biologic treatment to control interleukin 31, a key mediator in atopic dermatitis and prurigo nodularis. Actas Dermosifiliogr. 2022;113(7):674\u201384.","journal-title":"Actas Dermosifiliogr"},{"key":"741_CR17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","volume":"404","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. Lancet. 2024;404:445\u201360.","journal-title":"Lancet"},{"key":"741_CR18","unstructured":"Food and Drug Administration, Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments. 2022 [cited 2022 October 3]. https:\/\/www.fda.gov\/media\/159500\/download. Accessed 6 June 2024."},{"issue":"4","key":"741_CR19","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/bjd.13720","volume":"172","author":"PA Nelson","year":"2015","unstructured":"Nelson PA. Getting under the skin: qualitative methods in dermatology research. Br J Dermatol. 2015;172(4):841\u20133.","journal-title":"Br J Dermatol"},{"issue":"5","key":"741_CR20","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/bjd.14532","volume":"174","author":"PA Nelson","year":"2016","unstructured":"Nelson PA. Exploring new worlds: expanding the reach of qualitative research in dermatology. Br J Dermatol. 2016;174(5):951\u20132.","journal-title":"Br J Dermatol"},{"issue":"2","key":"741_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2022.100172","volume":"3","author":"J Foster","year":"2023","unstructured":"Foster J, et al. Current utilization of qualitative methodologies in dermatology: a scoping review. JID Innov. 2023;3(2): 100172.","journal-title":"JID Innov"},{"issue":"6","key":"741_CR22","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1001\/jamadermatol.2023.0839","volume":"159","author":"MG Pascual","year":"2023","unstructured":"Pascual MG, Morris MA, Kohn LL. Publication trends of qualitative research in dermatology: a scoping review. JAMA Dermatol. 2023;159(6):648\u201358.","journal-title":"JAMA Dermatol"},{"key":"741_CR23","unstructured":"Food and Drug Administration, Patient-focused drug development: collecting comprehensive and representative input. Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. 2020 [cited 2024 June 06]. https:\/\/www.fda.gov\/media\/139088\/download. Accessed 6 June 2024."},{"issue":"1","key":"741_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00403-021-02321-z","volume":"315","author":"LEM de Wijs","year":"2023","unstructured":"de Wijs LEM, et al. Needs and preferences of patients regarding atopic dermatitis care in the era of new therapeutic options: a qualitative study. Arch Dermatol Res. 2023;315(1):75\u201383.","journal-title":"Arch Dermatol Res"},{"issue":"7","key":"741_CR25","first-page":"22","volume":"16","author":"AM Snyder","year":"2023","unstructured":"Snyder AM, et al. Atopic dermatitis: a qualitative study on the burdens of living with itchiness. J Clin Aesthet Dermatol. 2023;16(7):22\u20135.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"8","key":"741_CR26","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1007\/s13555-022-00777-z","volume":"12","author":"CE Kleyn","year":"2022","unstructured":"Kleyn CE, et al. Burden of moderate to severe atopic dermatitis in adults from France, Italy, and the UK: patient-reported outcomes and treatment patterns. Dermatol Ther (Heidelb). 2022;12(8):1947\u201365.","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-025-00741-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-025-00741-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-025-00741-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T13:23:27Z","timestamp":1756905807000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-025-00741-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["741"],"URL":"https:\/\/doi.org\/10.1007\/s40271-025-00741-x","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"27 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was funded by Galderma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"J.I.S. has received honoraria as a consultant or advisory board member for AbbVie, Aldena, Amgen, AOBiome, Arcutis, Arena, Asana, Aslan, Attovia, BiomX, Biosion, Bodewell, Boehringer-Ingelheim, Bristol Myers Squibb, Cara, Castle Biosciences, Celgene, Connect Biopharma, Corevitas, Dermavant, Eli Lilly, Galderma, GSK, Incyte, Kiniksa, LEO Pharma, MyOr Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT Therapeutics, Recludix, Regeneron, Sanofi-Genzyme, Shaperon, Target RWE, and Union Therapeutics and his institution has received grants from Galderma, Incyte, and Pfizer. O.C., K.J., C.P., R.S., and J.P. are employees of Galderma, which funded this study. D.F., C.D.B., and D.R. are employees of Evidera, which received financial support from Galderma for work on this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"N\/A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Written informed consent to participate was sought prior to participation in the in-trial interview substudy.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"N\/A.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Jonathan I. Silverberg: writing\u2014review and editing, visualization, and supervision; Dina Filipenko: conceptualization, methodology, software, validation, formal analysis, investigation, resources, data curation, writing\u2014original draft, writing\u2014review and editing, visualization, supervision, project administration, and funding acquisition; Carla Dias Barbosa: conceptualization, methodology, validation, formal analysis, investigation, resources, data curation, writing\u2014original draft, writing\u2014review and editing, visualization, supervision, project administration, and funding acquisition; Danielle Rodriguez: conceptualization, methodology, validation, formal analysis, investigation, resources, data curation, writing\u2014review and editing, visualization, supervision, and project administration; Olivier Chambenoit: writing\u2014review and editing, visualization, and funding acquisition; Katrin Jack: writing\u2014review and editing, visualization, and funding acquisition; Christophe Piketty: writing\u2014review and editing, visualization, supervision, and funding acquisition; Ram Subramanian: visualization, supervision, and funding acquisition; and Jorge Puelles: conceptualization, resources, writing\u2014original draft, writing\u2014review and editing, visualization, supervision, project administration, and funding acquisition. All authors approved the final version of the manuscript and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}